The goals of this retrospective study were to determine whether there is a threshold hepatitis B virus (HBV) DNA value associated with spontaneous or antiviral therapy-related hepatitis B e antigen (HBeAg) clearance. We also investigated whether there is an HBV DNA value that can be used for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis B. HBV DNA levels in sequential serum samples of 165 Chinese patients with different stages of chronic HBV infection were quantified by a polymerase chain reaction (PCR)-based assay. Our results showed that almost all of the patients (83%) who remained HBeAg-positive had HBV DNA levels that were persistently above lo5 copies/mL. Serum HBV DNA levels decreased by a mean of 3 loglo in patients with HBeAg loss, but 5 1% had levels above lo5 copies/mL at the time HBeAg first became undetectable. Mean serum HBV DNA levels were significantly lower in HBeAg-negative patients. HBV DNA value above lo5 copies/mL would exclude all inactive carriers, but 45% of patients with HBeAgnegative chronic hepatitis would also be excluded if testing were only performed at presentation and 30% would be excluded if testing were performed on 3 occasions. In conclusion, serum HBV DNA levels decreased significantly in patients with HBeAg loss, but there was no threshold HBV DNA level associated with HBeAg clearance. Given the fluctuating course of HBeAg-negative chronic hepatitis, it is not possible to define a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis. 
DNA assays has improved our understanding of the pathogenesis and natural history of HBV infection and facilitated the monitoring of response to treatment, but it also has generated new questions and dilemmas.* Previous studies based on a single time point found that serum HBV DNA levels generally exceed lo5 copies/mL among patients with HBeAg-positive chronic hepatitis and may be as high as 1O'O copies/mL.'-7 Serum HBV DNA levels tended to be lower (lo4 to los copies/ mL) among patients with HBeAg-negative chronic hepatitis B (HBeAg-negative, anti-HBe-positive, elevated alanine aminotransferase [ALT])3,* and may be intermittently undetectable in non-PCR based assays.9,'O Until now, there have been very little data on what level of serum HBV DNA is associated with progressive liver disease. Consequently, there is no consensus on the level of serum HBV DNA when treatment is indicated.
A key question in the management of patients with HBeAg-positive chronic hepatitis B is to what level should serum HBV DNA be reduced to achieve sustained HBeAg seroconversion? To date, only 1 study had addressed this issue. In a study of 23 patients who received lamivudine therapy, 6 (50%) of HBeAg seroconversion, versus none of 11 whose serum HBV DNA remained > 1 O4 copies/mL.l This study suggested that there may be a threshold HBV DNA level associated with lamivudine-induced HBeAg seroconversion. However, this study was based on a very small number of patients. Thus, further studies are needed to validate this finding and to determine whether this threshold level applies to HBeAg seroconversion that occurs spontaneously or in association with other treatment. An arbitrary serum HBV DNA level of 1 O5 copies/mL has been proposed at the National Institutes of Health Workshop to differentiate chronic hepatitis B from an inactive carrier state (HBeAg-negative, persistently normal ALT).12 A recent study in France found that 98% of the inactive carriers had HBV DNA levels < lo5 copies/mL at presentation and 97% had an HBV DNA level persistently below lo5 copies/mL during a 1-to 6-year follow-up period. 13 The investigators concluded that their results support the National Institutes of Health recommendation of 1 O5 copies/mL as a cutoff HBV DNA value for differentiating inactive carriers from patients with chronic hepatitis B, but this study did not include patients with HBeAg-negative chronic hepatitis B for comparison. Another study in Greece found that a cutoff value of lo5 copies/mL would lead to misclassification of 13% of their patients with HBeAg-negative chronic hepatitis B and possibly denial of treatment. They suggested that a cutoff HBV DNA level of 3 X lo4 copies/mL is more appropriate for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis B. l 4
However, HBV DNA was tested at 1 time point only in this study. Thus, the appropriate HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis B remains to be determined.
We performed this retrospective study to measure quantitative HBV DNA levels in sequential serum samples of patients with different stages of chronic HBV infection. Our goals were to determine (1) whether there is a threshold HBV DNA value associated with spontaneous or antiviral therapy-related HBeAg seroconversion, and (2) the HBV DNA value that should be used for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis B.
Patients and Methods

Patients
This was a retrospective study using stored sera from Chinese patients with chronic HBV infection seen in the Hepatitis Clinic, Queen Mary Hospital, Hong Kong, between 1984 and 1992. Patients were seen every 3 to 6 months, or more often if clinically indicated. At each visit, liver biochemistry and HBV serology, including hepatitis B surface antigen (HBsAg), HBeAg, and anti-HBe, were checked. Serum was collected and stored frozen at -20°C for HBV DNA testing. All patients who had had at least 3 serum samples 1 year apart were studied. A total of 165 patients were included. These patients were classified into (Table 1) . Except for patients in groups 2B and 3B, none of the patients received antiviral therapy during the study period.
DeJnition
The upper limit of normal for serum ALT was 45 IU/L. HBeAg loss was defined as disappearance of serum 
Hepatitis B Serology
The hepatitis B serologic markers HBsAg, HBeAg, and anti-HBe were tested using commercially available enzyme-linked immunosorbent assay kits from Abbott Laboratories (North Chicago, IL).
Quuntajication of Serum HBV DNA Levels
Serum HBV DNA levels were quantified using the Cobas Amplicor HBV Monitor kits according to the manufacturer's instructions (Roche Molecular Systems, Inc., Branchburg, NJ).*~7,~5-l~ The lower limit of detection of this assay is 200 copies/mL (approximately 0.001 pg/mL) with a range of linearity up to 10' copies/mL.
Samples from patients who were HBeAg-positive were initially tested after a 1 in 1O0,OOO dilution; samples with undetectable HBV DNA were retested without dilution.
Samples from patients who were HBeAg-negative were initially tested undiluted; samples with HBV DNA results >lo6 copieslml were retested after 1 in 100,000 dilution. An arbitrary value of 100 copies/mL was assigned to samples with undetectable HBV DNA for statistical comparisons.
HBV Genotyping
The first available sample from each patient was used for HBV genotyping using a line-probe assay (Inno-Lipa HBV genotyping assay; Innogenetics, Inc., Ghent, Belgium) .18-20 All necessary precautions to prevent crosscontamination were observed, and negative controls were included at each step. T o validate the results of line probe assay, 10% randomly selected samples of genotypes B and C and all samples with genotype A or D were sent for bidirectional automated sequencing at the DNA sequencing core facility, University of Michigan Medical Center, using the standard protocol for the Applied Biosystems DNA sequencer 377 (Perkin Elmer Corp., Foster City, CA). Sequencing results were compared with published sequences to ascertain HBV genotypes.21,22 HBV genotype could be determined by line-probe assay in all patients who had detectable HBV DNA by PCR. Comparison between results of direct sequencing and the lineprobe assay showed 100% concordance.
Precore Stop Codon Variant (G189J) and Core Promotor Variant (AI~QT, G1764A)
Serial samples from patients with sustained HBeAg seroconversion (group 3) and initial samples of HBeAgnegative patients (groups 4 and 5 ) were tested for precore (PC) stop codon ((21894) and core promotor (CP) (A1762T, GI76&) variants using Inno-Lipa precore/core promotor kits (Innogenetics, Inc.). '9,20 Except for the primers, the procedure was similar to that for HBV genotyping. All samples with indeterminate results and 20% of randomly selected samples with PC and/or CP variant were sent for direct sequencing as described above. Indeterminate results were obtained in only 2% of samples in the PC and 9% in the CP region using the line-probe assay. Of the samples that could be typed, the concordance between the line-probe assay and sequencing was 99%. The line-probe assay was more sensitive in detecting mixed sequences than direct sequencing.
statistical Analyses
Results were expressed as mean i standard error. Data were entered into an Excel database and analyzed using SPSS version 9.0 software package (SPSS, Inc., Chicago, IL). Statistical analyses were performed using x2 and Fisher's exact test for categorical variables. Paired or unpaired Student's t test or one-way ANOVA with Tukey test was used for continuous variables as appropriate. Results were considered statistically significant at P < .OS.
Results
The demographics, baseline liver histology, results of HBV genotyping, and serial quantitative HBV DNA and ALT values are summarized in Tables 2 and 3 .
Group I: Persistently HBeAg-Positive, n = 27 Serum HBV DNA levels varied from 1O5-l0 copieslml with a slight (<1 loglo) decline during a mean follow-up of 43 t 3 months (range, 24 to 88 months) (Fig. 1A) . There was no correlation between serum HBV DNA and ALT levels. HBV DNA levels above lo5 copies/mL were observed in 96% of the samples. None of the patients in this group had HBV DNA levels persistently below lo5 copieslml. pearance of HBeAg (Fig. 1B) . There was no difference in absolute value or degree of decline of the HBV DNA level between patients with spontaneous or IFN-related transient HBeAg loss. patients. Serum HBV DNA levels decreased by a mean of 3 loglo to 10"' copies/mL when HBeAg first became undetectable (Fig. 1 C) variants at the time when HBeAg first became undetectable was similar between patients with and without sustained biochemical remission.
Group 4: HBdg-Negative With Pershmt or
Intmittentl AbnomalALT, n = 33
Comparedlvith patients who were HBeAg-positive, this group of patients had significantly lower serum HBV DNA levels; mean, 5.2 loglo versus 8.4 loglo copies/mL (P < .OO 1). There was a wide range in HBV DNA levels at presentation (1 03-8 copies/mL) (Fig.   1 D) and during the course of follow-up (Fig. 4) . About half (47%) of the samples had HBV DNA levels less than lo5 copies/mL. HBV DNA levels persistently greater than lo5, lo4, and lo3 copies/mL, were found in 33%, 58%, and 82% patients, respectively. Twenty- HEPATOLOGY, Val. 36, No. 6, 2002 CHU, HUSSAIN, AND LOK 1413 
Group 5 : HBeAg-Negative With Persistently Normal
A L T , n = 2 9
The HBV DNA level in this group was significantly lower than that of patients in group 4, the mean HBV DNA level at presentation being 3.1 loglo copies/mL (P < .OOl). At presentation, the CP variant as the dominant sequence was found in 30% of patients and the PC variant as the dominant sequence was found in 50% of patients (Table 6 ). HBV DNA levels remained stable during a mean follow-up period of 62 ? 3 months (range, 41 to 92 months). Twenty-six (90%) patients had detectable HBV DNA in at least 1 of their 3 samples, and 15 (52%) had persistently detectable serum HBV DNA. All of the samples had HBV DNA levels lower than lo5 copies/mL. Only 2 (7%) patients had HBV DNA levels persistently higher than lo4 copies/mL.
Discussion
In accordance with previous reports,'-' we found that more than 90% of HBeAg-positive patients had serum HBV DNA levels that could be detected by non-PCR assays, which have detection limits of lo5" copies/mL. In this study, the correlation between HBV DNA and ALT levels in HBeAg-positive patients was poor, possibly related to immune tolerance secondary to perinatal infection in many of our patients.
A previous small-scale study on lamivudine-treated patients suggested that HBV DNA levels must be reduced to less than lo4 copies/mL for HBeAg seroconversion to occur.' Our results showed a wide range in HBV DNA levels ( copies/mL) at the time HBeAg first became undetectable, implying that there is no threshold HBV DNA level for HBeAg clearance/seroconversion. This observation was true for spontaneous as well as IFN-related HBeAg clearance/seroconversion. Because our samples were collected in the prelamivudine era, we cannot ascer- core promotor variants after HBeAg loss was not necessarily associated with a higher HBV DNA or ALT level. In accordance with recent l i t e r a t~r e ,~~ not all patients with sustained HBeAg seroconversion had sustained biochemical remission. Although 36% of the patients without sustained biochemical remission had a transient ALT flare, the remaining 64% had intermittent or persistently abnormal ALT values. The latter pattern explains why some patients develop progressive liver disease despite sustained HBeAg seroconversion.
The National Institutes of Health workshop on management of hepatitis B proposed that a serum HBV DNA level of lo5 copies/mL be used to differentiate chronic hepatitis B from an inactive carrier state. 12 Our results showed that a HBV DNA value above lo5 copies/mL would exclude all inactive carriers but also 45% of patients with HBeAg-negative chronic hepatitis if testing were only performed at presentation and 30% if testing were performed on 3 occasions. Decreasing the cutoff value to 3 X lo4 copies/mL would misclassify 7% of inactive carriers and 30% of patients with HBeAg-negative chronic hepatitis if testing were only performed at presentation. Given the variable course of HBeAg-negative chronic hepatitis B, retesting on more than one occasion helps in differentiating patients with HBeAgnegative chronic hepatitis from inactive carriers, but no single HBV DNA value reliably differentiates these 2 groups. In accordance with other reports,'3 we found that serum HBV DNA remained detectable in the vast majority of inactive carriers, but HBV DNA levels tend to be lower and to remain stable over a 5-year follow-up period.
In summary, we found that serum HBV DNA levels were very high (lO5-I0 copieslml) in HBeAg-positive patients. Serum HBV DNA levels decreased by a mean of 3 loglo in patients who had spontaneous or IFN-related HBeAg loss, but there was no threshold HBV DNA level associated with HBeAg clearance. Serum HBV DNA level at the time of HBeAg loss was not a predictor of durability of HBeAg loss. A further decline in serum HBV DNA levels was observed in patients with sustained HBeAg loss regardless of anti-HBe seroconversion. Serum HBV DNA levels were significantly lower in HBeAg-negative patients, but levels as high as 109 copies/mL were detected. Although all of the inactive carriers had HBV DNA levels that were persistently below lo5 copies/mL, only 33% of patients with HBeAg-negative chronic hepatitis had HBV DNA levels that were persistently above lo5 copiesiml. Given the fluctuating course of HBeAgnegative chronic hepatitis B, it is not possible to define a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis.
